Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer

Sarah Hamidi,Ramona Dadu,Mark E. Zafereo,Renata Ferrarotto,Jennifer R. Wang,Anastasios Maniakas,G. Brandon Gunn,Anna Lee,Michael T. Spiotto,Priyanka C. Iyer,Luana G. Sousa,Neal S. Akhave,Salmaan Ahmed,Kim O. Learned,Charles Lu,Stephen Y. Lai,Michelle Williams,S. Mohsen Hosseini,Naifa L. Busaidy,Maria E. Cabanillas

DOI: https://doi.org/10.1001/jamaoncol.2024.2133

IF: 33.006

2024-07-11

JAMA Oncology

Abstract:Importance BRAF/MEK inhibitors revolutionized the treatment of BRAF V600E-variant anaplastic thyroid carcinoma ( BRAF v-ATC), offering improved outcomes for patients with this previously incurable disease. Observations Anaplastic thyroid carcinoma (ATC) accounts for approximately half of thyroid cancer−related deaths. It presents as a rapidly growing tumor that often invades locoregional structures and spreads to distant sites early; therefore, prompt diagnosis, staging, and treatment initiation are of the essence in the treatment of ATC. Although most oncologists will encounter a patient with ATC in their practice, the rarity of this disease makes treatment challenging, particularly because those with BRAF v-ATC no longer have a dismal prognosis. BRAF/MEK kinase inhibitors have transformed the outlook and treatment of BRAF v-ATC. Therefore, molecular profiling to identify these patients is critical. More recently, the addition of immunotherapy to BRAF/MEK inhibitors as well as the use of the neoadjuvant approach were shown to further improve survival outcomes in BRAF v-ATC. Many of these recent advances have not yet been incorporated in the currently available guidelines, allowing for disparities in the treatment of patients with BRAF v-ATC across the US. With the increasing complexity in the management of BRAF v-ATC, this Consensus Statement aims to formulate guiding recommendations from a group of experts to facilitate therapeutic decision-making. Conclusions and Relevance This Consensus Statement from the FAST (Facilitating Anaplastic Thyroid Cancer Specialized Treatment) group at MD Anderson Cancer Center emphasizes that rapid identification of a BRAF V600E pathogenic variant and timely initiation of sequential therapy are critical to avoid excess morbidity and mortality in patients with BRAF v-ATC. In the past decade, remarkable progress has been made in the treatment of patients with BRAF v-ATC, justifying these new evidence-based recommendations reached through a consensus of experts from a high-volume center.

oncology